Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
High Content Cell Based Assays in Drug Discovery: Changing the HTS Paradigm
HCS has evolved over the course of nearly two decades, enabling us to perform highly complex cellular based HCA screens, sometimes involving primary and human embryonic stem cells. With this development and acceptance as a screening platform, came data explosion requiring special logistics typically not associated with screening operations.
Add to Calendar ▼2013-01-22 00:00:002013-01-23 00:00:00Europe/LondonCellTech 2013CellTech 2013 in San Diego, CA, USASan Diego, CA, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
